Skip to main content
Medy-Tox Inc. logo

Medy-Tox Inc. — Investor Relations & Filings

Ticker · 086900 ISIN · KR7086900008 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2025-03-07 Proxy Solicitation & In…
Country KR South Korea
Listing KO 086900

About Medy-Tox Inc.

https://www.medytox.com/?site_id=en

Medy-Tox Inc. is a biopharmaceutical company focused on the research, development, and commercialization of biologic products. Its primary offerings are centered on botulinum toxin type A (BTX-A) formulations, including Neuronox®, INNOTOX®, Coretox®, and NEWLUX®, which are used for both aesthetic and therapeutic applications. The company is noted for developing the world's first liquid-injectable botulinum toxin. In addition to its toxin portfolio, Medy-Tox manufactures and markets a line of hyaluronic acid (HA) dermal fillers, such as Neuramis®, Atiere, and Potenfill. The company's product range also extends to dermocosmetics under the NEURADERM brand.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Medytox. It details the date, location, agenda items (including financial statement approval, director/auditor appointments, and remuneration limits), and information regarding electronic voting. This document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and request their participation/votes, which falls under the Proxy Solicitation & Information Statement category.
2025-03-07 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by Medytox. This falls under the category of a company reporting its own share buyback activities.
2025-02-03 Korean
[기재정정]타법인주식및출자증권처분결정
M&A Activity Classification · 1% confidence The document is a regulatory filing from Medytox regarding the 'Disposal of Shares and Securities of Other Corporations' (타법인주식및출자증권처분결정). It is a correction filing (정정신고) detailing the completion of a share sale of Evolus Inc. Since this document pertains to the disposal of assets/investments and does not fit into specific categories like M&A (which usually implies business combinations) or share buybacks (which is the company's own shares), it falls under the general regulatory filing category for corporate disclosures.
2025-01-14 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) from Medy-Tox, specifically detailing a 'Decision to Acquire Treasury Shares' (자기주식 취득 결정). This is a regulatory filing required by the Korea Exchange (KRX) when a company decides to buy back its own shares. According to the provided definitions, 'Transaction in Own Shares' (POS) is the correct category for reports regarding share buybacks.
2025-01-10 Korean
자기주식취득결과보고서
Transaction in Own Shares Classification · 1% confidence The document is a '자기주식취득결과보고서' (Report on the Results of Treasury Stock Acquisition) filed by Medy-Tox with the Financial Supervisory Service (FSS) in South Korea. It details the specific dates, quantities, and prices of shares repurchased by the company. According to the provided definitions, reports regarding a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2024-12-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement from Medytox regarding the setting of a record date for the purpose of holding an upcoming Annual General Meeting (AGM). It is not the AGM presentation itself, nor is it a proxy statement, but rather a standard regulatory notice regarding shareholder rights and meeting preparation. Given the nature of the announcement as a regulatory disclosure, it fits best under the RNS category.
2024-12-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.